Long-term safety of pegloticase in chronic gout refractory to conventional treatment

Annals of the Rheumatic Diseases

Volumn 72, Issue 9, 2013, Pages 1469-1474

  Becker, Michael A ^a   Baraf, Herbert S B ^b   Yood, Robert A ^c   Dillon, Aileen ^d   Vázquez Mellado, Janitzia ^e   Ottery, Faith D ^f   Khanna, Dinesh ^g   Sundy, John S ^h  

^a UNIVERSITY OF CHICAGO   (United States)

^b Center for Rheumatology and Bone Research   (United States)

^c Reliant Medical Group   (United States)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

^e HOSPITAL GENERAL DE MÉXICO   (Mexico)

^f Savient Pharmaceuticals Inc   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGLOTICASE; PLACEBO; URATE;

ADULT; AGED; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; CANADA; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; GOUT; HOT FLUSH; HUMAN; HYPOTENSION; INCIDENCE; INFUSION RELATED REACTION; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NEPHROLITHIASIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN NECROSIS; SWEATING; THROAT IRRITATION; TOPHUS; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; URTICARIA; VOMITING;

GOUT; RHEUMATOID ARTHRITIS; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DRUG RESISTANCE; ENZYMES, IMMOBILIZED; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; POLYETHYLENE GLYCOLS; RECURRENCE; TREATMENT OUTCOME; URATE OXIDASE; URIC ACID;

EID: 84881477605     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201795     Document Type: Article

References (19)

1. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
2. Hamburger M, Baraf HS, Adamson TC III, et al. Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011;123(6 Suppl 1):3-36.
3. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80. (Pubitemid 32202663)
4. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007;66:1056-8. (Pubitemid 47122319)
5. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-8. (Pubitemid 47585481)
6. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5. (Pubitemid 38725128)
7. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82.
8. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60. (Pubitemid 34856121)
9. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guidelines for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
10. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41.
11. Edwards NL. Treatment-failure gout: a moving target (editorial). Arthritis Rheum 2008;58:2587-90.
12. Brook RA, Forsythe A, Smeeding JE, et al. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 2010;26:2813-21.
13. Doghramji PP, Edwards NL, McTigue J. Managing gout in the primary care setting: what you and your patients need to know. Am J Med 2010;123:S2.
14. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68. (Pubitemid 350186186)
15. Krystexxa® ( pegloticase) Injection, for intravenous infusion. Prescribing information. East Brunswick, NJ: Savient Pharmaceuticals, 2010.
16. Schlesinger N, Yasothan U, Kirkpatrick P. Pegloticase. Nat Rev Drug Discov 2011;10:17-18.
17. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. JAMA 2011;306:711-20.
18. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
19. Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Safety 2007;30:93-105. (Pubitemid 46193061)